1. Methylphenidate as a treatment option for substance use disorder: a transdiagnostic perspective
- Author
-
Peter van Ruitenbeek, Luisa Franzen, Natasha Leigh Mason, Peter Stiers, and Johannes G. Ramaekers
- Subjects
addiction ,attention deficit hyperactivity disorder ,psychopharmacology ,methylphenidate (MPH) ,cognitive control ,Psychiatry ,RC435-571 - Abstract
A transition in viewing mental disorders from conditions defined as a set of unique characteristics to one of the quantitative variations on a collection of dimensions allows overlap between disorders. The overlap can be utilized to extend to treatment approaches. Here, we consider the overlap between attention-deficit/hyperactivity disorder and substance use disorder to probe the suitability to use methylphenidate as a treatment for substance use disorder. Both disorders are characterized by maladaptive goal-directed behavior, impaired cognitive control, hyperactive phasic dopaminergic neurotransmission in the striatum, prefrontal hypoactivation, and reduced frontal cortex gray matter volume/density. In addition, methylphenidate has been shown to improve cognitive control and normalize associated brain activation in substance use disorder patients and clinical trials have found methylphenidate to improve clinical outcomes. Despite the theoretical basis and promising, but preliminary, outcomes, many questions remain unanswered. Most prominent is whether all patients who are addicted to different substances may equally profit from methylphenidate treatment.
- Published
- 2023
- Full Text
- View/download PDF